Virus vectors for immunoprophylaxis

AIDS Reviews

Volumn 2, Issue 3, 2000, Pages 127-135

  De Giuli Morghen, C ^a   Radaelli, A ^a   Zanotto, C ^a   Marconi, P ^a   Manservigi, R ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Adenoviral vectors; Alphatogavirus vectors; Avipoxvirus vectors; Herpesvirus vectors; HIV; Immune response; Immunoprophylaxis of viral diseases; Recombinant viruses; Vaccines

Indexed keywords

DRUG CARRIER; RECOMBINANT VACCINE; VACCINE; VIRUS DNA; VIRUS RNA; VIRUS VECTOR;

ADENOVIRUS; ALPHA VIRUS; BIOMEDICAL ENGINEERING; CYTOTOXICITY; DRUG DELIVERY SYSTEM; FOREIGN BODY; GENE; GENE EXPRESSION; HERPES VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNOPROPHYLAXIS; IN VIVO STUDY; INFECTION; INFECTION CONTROL; MICROORGANISM; NONHUMAN; PICORNAVIRUS; POXVIRUS; PROTECTION; REVIEW; SAFETY; TOGAVIRUS; VACCINATION; VIRAL GENETICS; VIRUS RECOMBINANT; VIRUS REPLICATION;

EID: 0034544488     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Construction of poxviruses as cloning vectors: Insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus
2. Vaccinia virus: A selectable eukaryotic cloning and expression vector
3. Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus
4. Humoral and cell-mediated immunity in rabbits immunized with live non-replicating avipox recombinants expressing the HIV-1SF2 env gene
5. Correlation between the immune response elicited in rabbits by env-recombinant avipox vaccines and the inhibition of HIV-1-specific functions
6. Response of monkeys to vaccination with recombinant vaccinia virus which coexpress HIV gp160 and human interleukin-2
7. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults
8. Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen
9. Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters
10. Construction of live vaccines by using genetically engineered poxviruses: Biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin
11. Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells
12. Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response
13. Carboxy-terminally truncated dengue virus envelope glycoproteins expressed on the cell surface and secreted extracellularly exhibit increased immunogenicity in mice
14. A non-structural viral protein expressed by a recombinant vaccinia virus protects against lethal cytomegalovirus infection
15. Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F Vac-G recombinants is mediated by antibodies
16. Evaluation in non-human primates of the safety, immunogenicity and efficacy of recombinant vaccinia viruses expressing the F G glycoprotein of respiratory syncytial virus
17. Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene
18. Oral vaccination of the fox against rabies using a live recombinant vaccinia virus
19. Vaccinia virus recombinants expressing rabiesvirus glycoprotein protect against rabies
20. pUV I: A new vaccinia virus insertion and expression vector
21. Structure of vaccinia virus late promoters
22. Expression of polyomavirus virion proteins by a vaccinia virus vector: Association of VP1 and VP2 with the nuclear framework
23. Oligonucleotide sequence signaling transcriptional termination of vaccinia virus early genes
24. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes
25. Reverse guanine phosphoribosyl-transferase selection of recombinant vaccinia viruses
26. Cloning and expression of foreign genes in vaccinia virus, using a host range selection system
27. Plaque size phenotype as a selectable marker to generate vaccinia virus recombinants
28. NYVAC: A highly attenuated strain of vaccinia virus
29. Virulence and immunogenicity of a modified vaccinia virus (strain MVA)
30. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence
31. Gene structures of low-neurovirulent vaccinia virus LC16m0, LC16m8, and their Lister original (LO) strains
32. Effects and virulences of recombinant vaccinia viruses derived from attenuated strains that express the human T-cell leukemia virus type I envelope gene
33. Fowlpox virus as a vector in non-avian species
34. Nonreplicating viral vectors as potential vaccines: Recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins
35. Beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques
36. Correlation between the immune response elicited in rabbits by env-recombinant avipox vaccines and the inhibition of HIV-1 specific functions
37. The use of an E1-deleted, replication-defective adenovirus recombinant expressing the rabies virus glycoprotein for early vaccination of mice against rabies virus
38. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization
39. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization
40. Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus
41. Defective adenoviruses as novel vaccines for the Flaviviridae
42. Viral vectors for gene therapy
43. US gene therapy in crisis
44. Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model
45. Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees
46. High level expression of the envelope glycoproteins of the human immunodeficiency virus type I in presence of rev gene using helper-independent adenovirus type 7 recombinants
47. Engineering herpes simplex virus vectors for human gene therapy
48. Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells
49. An enhanced packaging system for helper-dependent herpes simplex virus vectors
50. Replication-defective herpes simplex virus vectors for gene transfer in vivo
51. Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term expression in neurons
52. The function of herpes simplex virus genes: A primer for genetic engineering of novel vectors
53. Herpes virus vectors
54. Defective herpes simplex virus type 1 vectors harboring gag, pol, and env genes can be used to rescue defective retrovirus vectors
55. Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection
56. Vaccine potential of a Herpes simplex virus type 1 mutant with an essential glycoprotein deleted
57. Expression of the human immunodeficiency virus gag gene products by a replication-incompetent herpes simplex virus vector
58. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: Construction and evaluation in rodents
59. Mapping of herpes simplex virus-1 neurovirulence to g1 34.5, a gene nonessential for growth in culture
60. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation in mice
61. Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors
62. Infection initiated by the RNA pregenome of a DNA virus
63. Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses
64. Processing in the hepatitis C virus E2-NS2 region: Identification of p7 and two distinct E2-specific products with different C termini
65. Infectious Sindbis virus transient expression vectors for studying antigen processing and presentation
66. Human papillomavirus type 16 capsid proteins produced from recombinant Semliki Forest virus assemble into virus-like particles
67. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp 160 vaccine and by a gp 120 subunit vaccine
68. Expression of HIV-1 envelope glycoproteins by Semliki Forest virus vectors
69. Infectious particles derived from Semliki Forest virus vectors encoding murine leukemia virus envelopes
70. Reducing cytotoxicity induced by Sindbis viral vectors
71. Genetic determinants of Sindbis virus neuroinvasiveness
72. Semliki Forest virus: Cause of a fatal case of human encephalitis
73. An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies
74. Poliovirus chimeras expressing sequences from the principal neutralization domain of human immunodeficiency virus type 1
75. Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: Stimulation of humoral, mucosal, and cellular immunity
76. Study of the immunogenicity of different recombinant Mengo viruses expressing HIV1 and SIV epitopes
77. Parvovirus-like particles as vaccine vectors
78. Double-layered membrane vesicles released from mammalian cells infected with Sendai virus expressing the matrix protein of vesicular stomatitis virus
79. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3
80. The use of yellow fever virus modified by in vitro cultivation for human immunization
81. Recombinant rabies virus as potential live-viral vaccines for HIV-1
82. Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion
83. High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses